CORVUS PHARMACEUTICALS INC's ticker is CRVS and the CUSIP is 221015100. A total of 62 filers reported holding CORVUS PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $103,489 | -46.4% | 70,883 | -16.0% | 0.00% | 0.0% |
| Q2 2023 | $193,203 | -16.4% | 84,368 | -0.6% | 0.00% | -50.0% |
| Q2 2020 | $231,000 | +27.6% | 84,918 | -0.8% | 0.00% | 0.0% |
| Q1 2020 | $181,000 | -59.3% | 85,604 | +4.7% | 0.00% | -33.3% |
| Q4 2019 | $445,000 | +97.8% | 81,800 | +9.5% | 0.00% | +50.0% |
| Q3 2019 | $225,000 | -6.6% | 74,725 | +16.2% | 0.00% | 0.0% |
| Q2 2019 | $241,000 | +1.7% | 64,325 | +9.1% | 0.00% | 0.0% |
| Q1 2019 | $237,000 | +29.5% | 58,951 | +18.3% | 0.00% | +100.0% |
| Q4 2018 | $183,000 | -55.8% | 49,850 | +3.3% | 0.00% | -50.0% |
| Q3 2018 | $414,000 | -20.8% | 48,250 | +1.4% | 0.00% | -33.3% |
| Q2 2018 | $523,000 | +1.6% | 47,600 | +6.5% | 0.00% | 0.0% |
| Q1 2018 | $515,000 | +56.5% | 44,700 | +40.6% | 0.00% | +50.0% |
| Q4 2017 | $329,000 | -23.8% | 31,800 | +17.3% | 0.00% | -33.3% |
| Q3 2017 | $432,000 | +59.4% | 27,100 | +21.0% | 0.00% | +50.0% |
| Q2 2017 | $271,000 | – | 22,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 3,275,616 | $8,746,000 | 1.82% |
| Telemetry Investments, L.L.C. | 263,975 | $705,000 | 0.97% |
| CHI Advisors LLC | 719,132 | $1,920,000 | 0.45% |
| BVF INC/IL | 3,678,626 | $9,822,000 | 0.37% |
| EcoR1 Capital, LLC | 3,579,377 | $9,557,000 | 0.36% |
| Orbimed Advisors | 8,053,298 | $21,502,000 | 0.22% |
| Stonepine Capital Management, LLC | 46,886 | $125,000 | 0.06% |
| Ikarian Capital, LLC | 100,000 | $267,000 | 0.02% |
| ALGERT GLOBAL LLC | 19,737 | $53,000 | 0.02% |
| Windsor Creek Advisors, LLC | 14,786 | $39,000 | 0.01% |